See‐Tong Pang

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2

Lian Dee Ler, Sujoy Ghosh, Xiaoran Chai et al. · Science Translational Medicine · 2017 · 211 citations

Medicine, Molecular Biology, Oncology +12

REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer

Craig K. Svensson, J.A. Ceder, Diego Iglesias‐Gato et al. · Nucleic Acids Research · 2013 · 154 citations · Full text

Medicine, Endocrinology, Oncology +17

Pim‐1 expression in prostatic intraepithelial neoplasia and human prostate cancer

Alexander Valdman, Xiaolei Fang, See‐Tong Pang et al. · The Prostate · 2004 · 128 citations

Medicine, Oncology, Urology +17

Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer

Mu‐Yi Hua, Hung‐Wei Yang, Cheng‐Keng Chuang et al. · Biomaterials · 2010 · 128 citations

Pharmacy, Oncology, Pharmaceutics +16